Improved insulin sensitivity in response to PXL770 treatment may be consistent with predictions based on several lines of preclinical evidence and suggest the potential for longer term therapeutic utility in diabetes as well as in the context of NAFLD-NASH15,16 or other disorders such as polycystic ovary syndrome44 in which insulin resistance is a central component of pathophysiology. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.